In the preceding three months, 17 analysts have released ratings for Celanese CE, presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 6 | 8 | 2 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 3 | 1 | 0 |
| 2M Ago | 1 | 4 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 3 | 1 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Celanese, presenting an average target of $155.65, a high estimate of $184.00, and a low estimate of $128.00. Experiencing a 8.06% decline, the current average is now lower than the previous average price target of $169.29.
Decoding Analyst Ratings: A Detailed Look
The standing of Celanese among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Charles Neivert | Piper Sandler | Lowers | Neutral | $150.00 | $180.00 |
| David Begleiter | Deutsche Bank | Lowers | Hold | $135.00 | $160.00 |
| Steve Byrne | B of A Securities | Lowers | Underperform | $128.00 | $137.00 |
| Arun Viswanathan | RBC Capital | Lowers | Outperform | $167.00 | $168.00 |
| John McNulty | BMO Capital | Lowers | Market Perform | $138.00 | $142.00 |
| Michael Leithead | Barclays | Lowers | Equal-Weight | $151.00 | $170.00 |
| Aleksey Yefremov | Keybanc | Lowers | Overweight | $178.00 | $180.00 |
| Michael Sison | Wells Fargo | Lowers | Overweight | $165.00 | $180.00 |
| Ghansham Panjabi | Baird | Lowers | Outperform | $150.00 | $180.00 |
| Jeffrey Zekauskas | JP Morgan | Lowers | Neutral | $130.00 | $156.00 |
| Aleksey Yefremov | Keybanc | Lowers | Overweight | $180.00 | $190.00 |
| Joshua Spector | UBS | Lowers | Buy | $184.00 | $193.00 |
| Patrick Cunningham | Citigroup | Lowers | Neutral | $148.00 | $167.00 |
| Michael Sison | Wells Fargo | Lowers | Overweight | $180.00 | $195.00 |
| John McNulty | BMO Capital | Maintains | Market Perform | $158.00 | $158.00 |
| David Begleiter | Deutsche Bank | Lowers | Hold | $160.00 | $175.00 |
| Steve Byrne | B of A Securities | Lowers | Underperform | $144.00 | $147.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celanese. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celanese compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Capture valuable insights into Celanese's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Celanese analyst ratings.
About Celanese
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
Key Indicators: Celanese's Financial Health
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining Celanese's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -5.15% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Celanese's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 5.85%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.18%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Celanese's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.6%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.87, caution is advised due to increased financial risk.
The Core of Analyst Ratings: What Every Investor Should Know
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
